He Xu

1.4k total citations · 1 hit paper
15 papers, 773 citations indexed

About

He Xu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, He Xu has authored 15 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in He Xu's work include Ferroptosis and cancer prognosis (4 papers), Cancer, Lipids, and Metabolism (3 papers) and Prostate Cancer Treatment and Research (3 papers). He Xu is often cited by papers focused on Ferroptosis and cancer prognosis (4 papers), Cancer, Lipids, and Metabolism (3 papers) and Prostate Cancer Treatment and Research (3 papers). He Xu collaborates with scholars based in China, United States and Netherlands. He Xu's co-authors include Yanlun Gu, Yimin Cui, Zhiwei Qiu, Hanxu Zhang, Zhiyan Liu, Ran Xie, Nan Zhao, Qian Xiang, Xiaocong Pang and Xiaocong Pang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and British Journal of Cancer.

In The Last Decade

He Xu

12 papers receiving 763 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting integrin pathways: mechanisms and advances in therapy

2023 610 citations Xiaocong Pang, He Xu et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
He Xu China	7	340	134	131	125	106	15	773
Yanlun Gu China	7	324 1.0×	127 0.9×	131 1.0×	131 1.0×	110 1.0×	12	780
Ran Xie China	9	373 1.1×	117 0.9×	120 0.9×	128 1.0×	118 1.1×	19	826
Zhiyan Liu China	8	332 1.0×	136 1.0×	115 0.9×	107 0.9×	93 0.9×	30	799
Hanxu Zhang China	9	320 0.9×	113 0.8×	118 0.9×	124 1.0×	121 1.1×	31	835
Amanda Del Rosario United States	14	533 1.6×	189 1.4×	80 0.6×	69 0.6×	115 1.1×	23	1.0k
Carla Guenther Finland	9	312 0.9×	189 1.4×	137 1.0×	292 2.3×	109 1.0×	14	841
Marc Llort Asens Finland	7	241 0.7×	163 1.2×	131 1.0×	277 2.2×	91 0.9×	7	707
Brian A. MacDonald United States	9	388 1.1×	231 1.7×	162 1.2×	93 0.7×	172 1.6×	13	923
Alexis Broisat France	18	342 1.0×	144 1.1×	128 1.0×	184 1.5×	73 0.7×	66	1.1k

Countries citing papers authored by He Xu

Since Specialization

Citations

This map shows the geographic impact of He Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by He Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites He Xu more than expected).

Fields of papers citing papers by He Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by He Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by He Xu. The network helps show where He Xu may publish in the future.

Co-authorship network of co-authors of He Xu

This figure shows the co-authorship network connecting the top 25 collaborators of He Xu. A scholar is included among the top collaborators of He Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with He Xu. He Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Huang, Ziyang, He Xu, Lin Han, & Quan Zhou. (2025). An updated overview of lipid-regulated immunobiology in macrophages. Acta Biochimica et Biophysica Sinica. 58(1). 137–155.

Li, Duoduo, et al.. (2025). The PI3K/AKT/mTOR Pathway and Oral Diseases: A Bibliometric Analysis From 2008 to 2025. Clinical and Experimental Dental Research. 11(5). e70238–e70238.

Zhang, Junling, Qingqing Xiong, Xin Wang, et al.. (2024). Targeting SLITRK4 Restrains Proliferation and Liver Metastasis in Colorectal Cancer via Regulating PI3K/AKT/NFκB Pathway and Tumor‐Associated Macrophage. Advanced Science. 12(1). e2400367–e2400367. 6 indexed citations

Xu, He, et al.. (2024). Research Progress in Predicting Hepatocellular Carcinoma with Portal Vein Tumour Thrombus in the Era of Artificial Intelligence. Journal of Hepatocellular Carcinoma. Volume 11. 1429–1438. 1 indexed citations

Lei, Yalan, Jin Xu, Mingming Xiao, et al.. (2024). Pirfenidone alleviates fibrosis by acting on tumour–stroma interplay in pancreatic cancer. British Journal of Cancer. 130(9). 1505–1516. 6 indexed citations

Xu, He, Jian Wang, Yanlun Gu, et al.. (2024). IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities. Pharmacological Research. 201. 107063–107063. 16 indexed citations

Gu, Yanlun, Ying Zhou, Jixin Zhang, et al.. (2024). Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer. Advanced Healthcare Materials. 13(28). e2400673–e2400673. 7 indexed citations

Gu, Yanlun, Ying Zhou, Jixin Zhang, et al.. (2024). Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer (Adv. Healthcare Mater. 28/2024). Advanced Healthcare Materials. 13(28).

Pang, Xiaocong, He Xu, Zhiwei Qiu, et al.. (2023). Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 8(1). 1–1. 610 indexed citations breakdown →

10.

Gu, Yanlun, He Xu, Zhiwei Qiu, et al.. (2023). The challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials. Pharmacological Research. 189. 106694–106694. 36 indexed citations

11.

Zuo, Peng, Hongyi Chen, He Xu, et al.. (2023). Structural insights into the conformational changes of BTR1/SLC4A11 in complex with PIP2. Nature Communications. 14(1). 6157–6157. 11 indexed citations

12.

Lu, Xiaoqing, et al.. (2023). DMBT1 Alleviates Nasal Airway Inflammatory Response in the LPS-Induced Nasal Polyp Model. International Archives of Allergy and Immunology. 184(8). 808–813. 3 indexed citations

13.

Wu, Yingchao, Junling Zhang, Yanlun Gu, et al.. (2023). A novel immunogenic cell death–related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer. Frontiers in Immunology. 14. 1162876–1162876. 2 indexed citations

14.

Pang, Xiaocong, Junling Zhang, He Xu, et al.. (2021). SPP1 Promotes Enzalutamide Resistance and Epithelial‐Mesenchymal‐Transition Activation in Castration‐Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways. Oxidative Medicine and Cellular Longevity. 2021(1). 1258–5806602. 53 indexed citations

15.

Xu, He, Min-Sik Lee, Natasha Curry, et al.. (2018). Ablation of insulin receptor substrates 1 and 2 suppresses Kras -driven lung tumorigenesis. Proceedings of the National Academy of Sciences. 115(16). 4228–4233. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact